All In Biotech

Drug Trial Radar · NCT05875961

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

A Phase 1, Randomized, Observer-Blind, Multi-Center, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-derived A/H2N3 Subunit Influenza Virus Vaccine in Healthy Subjects 18 Years and Above

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Jun 15, 2023

Primary completion

Nov 15, 2024

Study completion Nov 15, 2024

Sponsor

Lead sponsor
SeqirusIndustry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
May 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine. Approximately 600 healthy adult subjects are to be randomized into 1 of 6 possible treatment groups with 100 subjects per group, stratified by age group (born after or before 1968). Each subject will receive an influenza vaccine injection on Day 1 and Day 22. Subjects will be followed up for approximately 12 months after the second vaccine injection. The primary immunogenicity analysis is based on the Day 1, Day 8, Day 22, Day 29, and Day 43 serology data. The primary safety analysis is based on solicited local and systemic adverse events (AEs) reported within 10 days after each vaccination, unsolicited AEs reported within 3 weeks after each vaccination, and serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal from the study, and AEs of special interest (AESIs) reported throughout the study.

Conditions

  • Influenza, Human
  • Infections
  • Respiratory Tract Infections
  • Virus Diseases
  • Infection Viral

Interventions

  • Low dose A/H2N3c + standard dose MF59Biological

    Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

  • Intermediate dose A/H2N3c + standard dose MF59Biological

    Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

  • High dose A/H2N3c + standard dose MF59Biological

    Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

  • High dose A/H2N3c non-adjuvantedBiological

    Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine

  • Lowest dose A/H2N3c + high dose MF59Biological

    Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

  • Low dose A/H2N3c + high dose MF59Biological

    Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean titer (GMT) of hemagglutination inhibition (HI) antibodies against homologous H2N3 strain - Day 1Time frame: Day 1
  2. GMT of HI antibodies against homologous H2N3 strain - Day 8Time frame: Day 8
  3. GMT of HI antibodies against homologous H2N3 strain Day 22Time frame: Day 22
  4. GMT of HI antibodies against homologous H2N3 strain - Day 29Time frame: Day 29
  5. GMT of HI antibodies against homologous H2N3 strain - Day 43Time frame: Day 43
  6. GMT of microneutralization (MN) antibodies against homologous H2N3 strain - Day 1Time frame: Day 1
  7. GMT of MN antibodies against homologous H2N3 strain - Day 8Time frame: Day 8
  8. GMT of MN antibodies against homologous H2N3 strain - Day 22Time frame: Day 22
  9. GMT of MN antibodies against homologous H2N3 strain - Day 29Time frame: Day 29
  10. GMT of MN antibodies against homologous H2N3 strain - Day 43Time frame: Day 43
  11. Geometric mean fold increase (GMFI) of HI antibodies against homologous H2N3 strain - Day 8Time frame: Day 8
  12. GMFI of HI antibodies against homologous H2N3 strain - Day 22Time frame: Day 22
  13. GMFI of HI antibodies against homologous H2N3 strain - Day 29Time frame: Day 29
  14. GMFI of HI antibodies against homologous H2N3 strain - Day 43Time frame: Day 43
  15. GMFI of MN antibodies against homologous H2N3 strain - Day 8Time frame: Day 8
  16. GMFI of MN antibodies against homologous H2N3 strain - Day 22Time frame: Day 22
  17. GMFI of MN antibodies against homologous H2N3 strain - Day 29Time frame: Day 29
  18. GMFI of MN antibodies against homologous H2N3 strain - Day 43Time frame: Day 43
  19. Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 1Time frame: Day 1
  20. Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 8Time frame: Day 8
  21. Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 22Time frame: Day 22
  22. Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 29Time frame: Day 29
  23. Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 43Time frame: Day 43
  24. Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 1Time frame: Day 1
  25. Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 8Time frame: Day 8
  26. Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 22Time frame: Day 22
  27. Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 29Time frame: Day 29
  28. Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 43Time frame: Day 43
  29. Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 8Time frame: Day 8
  30. Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 22Time frame: Day 22
  31. Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 29Time frame: Day 29
  32. Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 43Time frame: Day 43
  33. Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 8Time frame: Day 8
  34. Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 22Time frame: Day 22
  35. Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 29Time frame: Day 29
  36. Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 43Time frame: Day 43
  37. Number and percentages of subjects reporting solicited local and systemic adverse events (AEs) - Day 1 through Day 10Time frame: Day 1 through Day 10
  38. Number and percentages of subjects reporting solicited local and systemic AEs - Day 22 through Day 31Time frame: Day 22 through Day 31
  39. Number and percentage of subjects reporting any unsolicited AEsTime frame: Day 1 through Day 43
  40. Number and percentage of subjects reporting serious AEs (SAEs), AEs leading to withdrawal, AEs of special interest (AESI) and medically attended AEs (MAAEs)Time frame: Day 1 through Day 387

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Meridian Clinical Research

    Rockville, Maryland

  • Meridian Clinical Research

    Lincoln, Nebraska

  • Meridian Clinical Research

    Omaha, Nebraska

  • West Visayas State University Medical Center

    Iloilo City, Philippines

  • Manila Doctors Hospital

    Manila, Philippines

  • Quirino Memorial Medical Center

    Quezon City, Philippines

  • Silang Specialists Medical Center

    Silang, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.